IL221062D0 - Stitched polypeptides - Google Patents

Stitched polypeptides

Info

Publication number
IL221062D0
IL221062D0 IL221062A IL22106212A IL221062D0 IL 221062 D0 IL221062 D0 IL 221062D0 IL 221062 A IL221062 A IL 221062A IL 22106212 A IL22106212 A IL 22106212A IL 221062 D0 IL221062 D0 IL 221062D0
Authority
IL
Israel
Prior art keywords
stitched polypeptides
polypeptides
stitched
inventive stitched
making
Prior art date
Application number
IL221062A
Other versions
IL221062A (en
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US90856607P priority Critical
Priority to PCT/US2008/058575 priority patent/WO2008121767A2/en
Application filed by Harvard College filed Critical Harvard College
Publication of IL221062D0 publication Critical patent/IL221062D0/en
Publication of IL221062A publication Critical patent/IL221062A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides inventive stitched polypeptides, pharmaceutical compositions thereof, and methods of making and using inventive stitched polypeptides.
IL221062A 2007-03-28 2012-07-22 Stitched polypeptides IL221062A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US90856607P true 2007-03-28 2007-03-28
PCT/US2008/058575 WO2008121767A2 (en) 2007-03-28 2008-03-28 Stitched polypeptides

Publications (2)

Publication Number Publication Date
IL221062D0 true IL221062D0 (en) 2012-08-30
IL221062A IL221062A (en) 2018-06-28

Family

ID=39808865

Family Applications (2)

Application Number Title Priority Date Filing Date
IL201227A IL201227A (en) 2007-03-28 2009-09-29 Stitched polypeptides
IL221062A IL221062A (en) 2007-03-28 2012-07-22 Stitched polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL201227A IL201227A (en) 2007-03-28 2009-09-29 Stitched polypeptides

Country Status (12)

Country Link
US (3) US8592377B2 (en)
EP (3) EP2508531B1 (en)
JP (4) JP5631201B2 (en)
KR (3) KR101623985B1 (en)
CN (1) CN101730708B (en)
AU (1) AU2008232709C1 (en)
BR (1) BRPI0809366A8 (en)
CA (1) CA2682174A1 (en)
ES (2) ES2430067T3 (en)
HK (1) HK1140215A1 (en)
IL (2) IL201227A (en)
WO (1) WO2008121767A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
WO2008061192A2 (en) 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized maml peptides and uses thereof
CN105061577A (en) * 2006-12-14 2015-11-18 爱勒让治疗公司 Bis-sulfhydryl macrocyclization systems
ES2558928T3 (en) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN104086641A (en) 2007-02-23 2014-10-08 爱勒让治疗公司 Triazole macrocycle systems
JP5631201B2 (en) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ Stitched polypeptide
WO2008137633A2 (en) * 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
CA2710964A1 (en) * 2007-12-31 2009-09-11 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
US20090275519A1 (en) * 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN102884074A (en) * 2008-09-22 2013-01-16 爱勒让治疗公司 Peptidomimetic macrocycles
ES2666458T3 (en) * 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. peptidomimetic macrocycles
CA2737921C (en) 2008-09-22 2019-01-15 Aileron Therapeutics, Inc. Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
AU2009305550B2 (en) 2008-10-17 2014-06-12 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
BRPI0920899A2 (en) 2008-11-24 2016-04-26 Aileron Therapeutics Inc Peptidomimetic macrocycles with improved properties
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2010253834B2 (en) * 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
US9163330B2 (en) 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
JP2013507927A (en) * 2009-10-14 2013-03-07 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Improved peptidomimetic macrocycles
US9272983B2 (en) * 2009-10-28 2016-03-01 Xellia Pharmaceuticals Aps 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides including bacitracins
US8685928B2 (en) 2010-02-12 2014-04-01 Dana-Farber Cancer Institute, Inc. Antagonists of MUC1
EA201390182A1 (en) * 2010-07-28 2014-01-30 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Glp-1 receptor compounds agonists containing stabilized areas
RU2582678C2 (en) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012061466A2 (en) * 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
CA2817568A1 (en) * 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
EP3360892A1 (en) 2011-04-15 2018-08-15 Dana-Farber Cancer Institute, Inc. Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2012174423A1 (en) * 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2793920A4 (en) * 2011-12-21 2015-07-01 Univ New York Proteolytically resistant hydrogen bond surrogate helices
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2925035A1 (en) * 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
KR20150131244A (en) * 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stapled and stitched polypeptides and uses thereof
EP2970417B1 (en) 2013-03-15 2019-06-19 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
AU2014227824B2 (en) 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
CA2906572A1 (en) * 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
CA2915354A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3052520A4 (en) * 2013-10-01 2017-12-06 President and Fellows of Harvard College Stabilized polypeptides and uses thereof
WO2015153560A1 (en) 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US10189887B2 (en) 2014-04-17 2019-01-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides and uses thereof for reducing CD95-mediated cell motility
US10471120B2 (en) * 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2989311A1 (en) 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017136652A1 (en) * 2016-02-04 2017-08-10 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
WO2018039545A2 (en) 2016-08-26 2018-03-01 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
WO2018174831A1 (en) * 2017-03-24 2018-09-27 Agency For Science, Technology And Research Stapled peptides
WO2019018499A2 (en) 2017-07-19 2019-01-24 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019118719A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
WO2019118893A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019157131A1 (en) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2019178313A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection

Family Cites Families (594)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000259A (en) 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
AU550730B2 (en) 1982-03-09 1986-04-10 Commonwealth Of Australia, The Automated metal detection
US4728726A (en) 1982-10-04 1988-03-01 The Salk Institute For Biological Studies GRF analogs IIIb
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US5416073A (en) 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4730006A (en) * 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US4880778A (en) 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
HU206890B (en) 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5112808A (en) 1987-05-11 1992-05-12 American Cyanamid Company Alkylated hormone-releasing peptides and method of treatig mammals therewith
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5453418A (en) 1988-03-07 1995-09-26 Eli Lilly And Company Ractopamine and growth hormone combinations
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
AU3439589A (en) 1988-03-24 1989-10-16 Terrapin Diagnostics, Inc. Molecular sticks for controlling protein conformation
US5094951A (en) 1988-06-21 1992-03-10 Chiron Corporation Production of glucose oxidase in recombinant systems
US5043322A (en) 1988-07-22 1991-08-27 The Salk Institute For Biological Studies Cyclic GRF analogs
US5245009A (en) 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto Syringe guide with adjustment of depth depth of needle in skin
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5384309A (en) 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5712418A (en) * 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5169932A (en) 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
US5580957A (en) 1989-10-30 1996-12-03 The Salk Institute For Biological Studies GnRH analogs
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
SK32693A3 (en) 1990-10-11 1993-09-09 Boehringer Ingelheim Kg Cyclopeptides, a method of preparing them and their use as drugs
DE69118826T2 (en) 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamide derivatives, their polymers, copolymers and their use
US5124454A (en) 1990-11-30 1992-06-23 Minnesota Mining And Manufacturing Company Polycyclic diamines and method of preparation
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0525838A3 (en) 1991-04-09 1993-02-10 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5262519A (en) 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
US5364851A (en) * 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
DE69220861D1 (en) 1991-08-13 1997-08-21 Takeda Chemical Industries Ltd Cyclic peptides and use thereof
EP0552417B1 (en) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
SE9102652D0 (en) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
IL103252A (en) 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6051554A (en) * 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
JP3067031B2 (en) * 1992-04-03 2000-07-17 カリフォルニア インスティチュート オブ テクノロジー Olefin metathesis polymerization methods
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
EP0643726B1 (en) 1992-05-26 1999-08-18 Rijksuniversiteit te Leiden PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0651761B1 (en) 1992-07-13 2002-10-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
DE69411154D1 (en) 1993-02-22 1998-07-23 Alza Corp Compositions for oral delivery of drugs
HUT72896A (en) 1993-03-29 1996-06-28 Du Pont Merck Pharma Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1994025482A1 (en) 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
ES2229045T3 (en) 1993-08-09 2005-04-16 Sod Conseils Rech Applic Derivatives of therapeutic peptides.
KR967005927A (en) 1993-11-22 1996-11-08 그레고리 기오타 p53- binding polypeptides and this code crystallized polynucleotide (p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME)
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
WO1995024176A1 (en) * 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5824483A (en) * 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
JP3166482B2 (en) 1994-06-07 2001-05-14 日産自動車株式会社 Coloring structure having a reflection interference effects
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) * 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US7553929B2 (en) 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5702908A (en) 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
CN1132012C (en) 1994-09-19 2003-12-24 里卡尔多·J·莫罗 Detection and treatment of cancer
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5681928A (en) 1994-12-16 1997-10-28 The Salk Institute For Biological Studies Betides and methods for screening peptides using same
US5807983A (en) 1995-12-28 1998-09-15 The Salk Institute For Biological Studies GNRH antagonist betides
WO1996020951A1 (en) 1994-12-29 1996-07-11 Massachusetts Institute Of Technology Chimeric dna-binding proteins
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
EP0729972A1 (en) 1995-02-28 1996-09-04 F. Hoffmann-La Roche Ag Peptide derivatives of tetrahydronaphthalene
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5675001A (en) 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
US5700775A (en) 1995-03-24 1997-12-23 Gutniak; Mark K. Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (en) 1995-03-31 1998-05-19 Emisphere Tech Inc Compound composition form unit dosage methods for administering a biologically active agent for preparing a composition for delivering an active agent to prepare a compound and pharmaceutical composition and
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane Analogs of growth hormone-releasing factor
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
MX9708500A (en) 1995-05-04 1998-02-28 Scripps Research Inst Synthesis of proteins by native chemical ligation.
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6020311A (en) 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
KR100543190B1 (en) 1995-05-26 2006-06-23 떼라떼끄놀로지 인코퍼레이티드 Chimeric fatty body with improved biological potency - Businesses - whether analogue RF
US6458764B1 (en) 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5811515A (en) * 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
FR2738151B1 (en) 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonists of the oncogenic activity of mdm2 protein, and their use in the treatment of cancers
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
WO1997023508A1 (en) 1995-12-22 1997-07-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
EP0880357A4 (en) 1996-01-17 1999-05-12 California Inst Of Techn Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
IL131368D0 (en) 1997-02-20 2001-01-28 Yeda Res & Dev Antipathogenic synthetic peptides and compositions comprising them
SI9720025A (en) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Compounds and compositions for delivering active agents
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP3792777B2 (en) 1996-05-10 2006-07-05 株式会社カネカ Method for producing 1-alkoxycarbonyl-3-phenylpropyl derivative
AU3220097A (en) 1996-05-22 1997-12-09 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
AT185146T (en) 1996-06-14 1999-10-15 Takeda Chemical Industries Ltd A process for removing N-terminal methionine
US5817627A (en) 1996-06-14 1998-10-06 Theratechnologies Inc. Long-acting galenical formulation for GRF peptides
US5663316A (en) * 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
DE69738754D1 (en) 1996-07-05 2008-07-17 Cancer Rec Tech Ltd Hemmer of interaction between p53 and mdm2
DE69713109D1 (en) 1996-07-22 2002-07-11 Novo Nordisk As Compounds with growth hormone releasing properties
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
US5856445A (en) * 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
CN101157924A (en) 1996-10-25 2008-04-09 人体基因组科学有限公司 Neutrophil leukocyte gene alpha
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
AU734337B2 (en) * 1996-11-21 2001-06-14 Promega Corporation Alkyl peptide amides and applications
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
EP1015479A4 (en) 1997-04-11 2002-07-24 Lilly Co Eli Combinatorial libraries of peptidomimetic macrocycles and processes therefor
GB9708092D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
WO1998051707A1 (en) 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6127341A (en) 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2304124A1 (en) * 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Bci-2-like protein bim and methods of use thereof
CA2305809A1 (en) 1997-09-26 1999-04-08 University Technologies International, Inc. Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) * 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
WO1999029343A1 (en) 1997-12-09 1999-06-17 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
AU755051B2 (en) 1998-01-07 2002-12-05 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L A device for controlling the depth 'of penetration of a needle, in particular applicable to a syringe for injections
US6030997A (en) 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6555156B1 (en) 1998-01-29 2003-04-29 Kinerton Limited Process for making absorbable microparticles
EP1053020B1 (en) 1998-01-29 2004-03-31 Poly-Med Inc. Absorbable microparticles
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU767185B2 (en) * 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
BR9909634A (en) 1998-04-15 2001-10-16 Aventis Pharm Prod Inc A process for preparing cyclic peptide analogs, and peptide suitable as an intermediate for carrying out the process
US6190699B1 (en) 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6194402B1 (en) 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
AT380548T (en) 1999-01-29 2007-12-15 Univ Illinois Use of p53 inhibitors for the treatment of side effects in cancer therapy
US6372490B1 (en) 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
WO2000052210A2 (en) 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
ID30262A (en) * 1999-03-29 2001-11-15 Procter & Gamble Melanocortin receptor ligands
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) * 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
AT296545T (en) 1999-04-27 2005-06-15 Aionix Invest Ltd Additional to the restoration of the growth hormone mirror
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2505617A1 (en) 1999-05-17 2000-11-23 Conjuchem Inc. Modified secretin and method of synthesizing thereof
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1180016B1 (en) 1999-05-24 2006-09-27 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
WO2001006988A2 (en) 1999-07-26 2001-02-01 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US6461634B1 (en) 1999-08-20 2002-10-08 Edward Marshall Food-based delivery of HGH-stimulating and other nutritional supplements
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20020016298A1 (en) 1999-09-01 2002-02-07 Hay Bruce A. Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
AT435871T (en) 1999-11-22 2009-07-15 Zymogenetics Inc Method for forming a peptide receptor complex with zsig33 polypeptides.
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6579967B1 (en) 1999-12-14 2003-06-17 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
AU1891801A (en) 1999-12-16 2001-06-25 Chugai Seiyaku Kabushiki Kaisha Method of screening remedy for cancer with the use of interaction domains of p53 and mortalin
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
DE10009341A1 (en) 2000-02-22 2001-09-06 Florian Kern A method for antigen-specific stimulation of T lymphocytes
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US20020002198A1 (en) 2000-04-17 2002-01-03 Parr Tyler B. Chemical synergy to elevate growth hormone release in vertebrates
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
CA2380423A1 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL143690D0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942D0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US7166712B2 (en) 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
IL144468D0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
US7049290B2 (en) * 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
BR0113178A (en) 2000-08-02 2004-04-06 Theratechnologies Inc biological modified peptides with increased potency
US20040228866A1 (en) 2000-08-04 2004-11-18 Ludwig Institute For Cancer Research Suppressor genes
AU8494201A (en) * 2000-08-16 2002-02-25 Univ Georgetown Med Center Small molecule inhibitors targeted at bcl-2
IL145106D0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
US20040106548A1 (en) 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
KR20030046411A (en) 2000-09-08 2003-06-12 그리폰 테라퓨틱스, 인코포레이티드 'Pseudo'-Native Chemical Ligation
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20030074679A1 (en) 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
JP2004530422A (en) 2000-12-19 2004-10-07 ザ ジョンズ ホプキンス ユニバーシティThe Johns Hopkins University To induce rapid apoptosis jfy1 protein
US20020091090A1 (en) 2000-12-28 2002-07-11 Cole Bridget M. Somatostatin antagonists and agonists
CU23157A1 (en) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION FOR TREATING TISSUE DAMAGE DUE TO LACK arterial blood supply
US7268113B2 (en) 2001-02-02 2007-09-11 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
AU2002247724B2 (en) 2001-02-23 2008-02-07 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
GB0104588D0 (en) 2001-02-24 2001-04-11 Univ Dundee Novel p-53 inducible protein
DE10109813A1 (en) 2001-03-01 2002-09-12 Thomas Stanislawski Tumor peptide antigen from human MDM2 proto-oncogene
WO2002072597A2 (en) 2001-03-09 2002-09-19 University Of Louisville Helicomimetics and stabilized lxxll peptidomimetics
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
HU0303727A2 (en) 2001-04-09 2004-03-01 The Administrators Of The Tulane Educational Fund Somatostatin agonists and their use
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US7208154B2 (en) 2002-06-03 2007-04-24 Regents Of The University Of Michigan Methods and compositions for the treatment of MHC-associated conditions
ES2309177T3 (en) 2001-06-05 2008-12-16 Elan Pharma International Limited System and method for milling materials.
JP2004536834A (en) 2001-07-06 2004-12-09 オークランド ユニサーヴィシズ リミテッド The treatment of hypertension
EP1422215A4 (en) 2001-08-08 2005-07-06 Kaneka Corp Process for producing optically active 2-substituted carboxylic acid
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20030157717A1 (en) 2001-09-07 2003-08-21 Baylor College Of Medicine Texas Medical Center Linear DNA fragments for gene expression
US20020045192A1 (en) 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
EP1312363A1 (en) 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US20030083241A1 (en) 2001-11-01 2003-05-01 Young Charles W. Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
AT552031T (en) 2001-12-18 2012-04-15 Alize Pharma Sas Pharmaceutical compositions containing non-acylated ghrelin for the treatment of insulin resistance
EP1321474A1 (en) 2001-12-18 2003-06-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for inducing apoptosis
WO2003055510A1 (en) 2001-12-24 2003-07-10 Auckland Uniservices Limited Therapy for growth hormone induced insulin resistance in juveniles with growth disorders
WO2003057158A2 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
WO2003059933A2 (en) 2002-01-03 2003-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conformationally constrained c-backbone cyclic peptides
AT510919T (en) 2002-02-07 2011-06-15 Baylor College Medicine Changed brain denture development after after hormon related high-treatment motor treatments released to therapy with growth hormone
EP1476178A4 (en) 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp Formulation strategies in stabilizing peptides in organic solvents and in dried states
US7432242B2 (en) 2002-02-15 2008-10-07 The Regents Of The University Of Michigan Inhibitors of RGS proteins
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
AU2003227066A1 (en) 2002-03-26 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
US7498134B2 (en) 2002-03-30 2009-03-03 The Trustees Of Columbia University In The City Of New York HAUSP-Mdm2 interaction and uses thereof
EP1499895B1 (en) 2002-04-22 2008-05-07 University Of Florida Functionalized nanoparticles and methods of use
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
EP1507769B2 (en) 2002-05-30 2017-10-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
WO2003102538A2 (en) 2002-05-30 2003-12-11 European Molecular Biology Laboratory Combinatorial chemical library ii
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20040081652A1 (en) 2002-07-15 2004-04-29 The Johns Hopkins University Neuronal and optic nerve gene expression patterns
AU2003259172A1 (en) 2002-07-24 2004-02-09 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
AU2003261774A1 (en) 2002-09-06 2004-03-29 Kaneka Corporation PROCESS FOR PRODUCING L-Alpha-METHYLCYSTEINE DERIVATIVE
US20040171809A1 (en) * 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
KR20050071498A (en) 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 Ghrh analogues
AU2003277891A1 (en) 2002-09-23 2004-04-08 Medivir Ab Hcv ns-3 serine protease inhibitors
DE60326623D1 (en) 2002-10-07 2009-04-23 Genome Res Ltd P53 binding polypeptide
EP1556084A4 (en) 2002-10-07 2006-01-11 Zymogenetics Inc Methods of regulating body weight
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
CA2501627C (en) 2002-10-24 2013-07-16 Dow Global Technologies Inc. Stabilization of olefin metathesis product mixtures
CA2505368C (en) 2002-11-07 2011-09-20 Kosan Biosciences Incorporated Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same
RU2312106C2 (en) * 2002-11-08 2007-12-10 Ф.Хоффманн-Ля Рош Аг Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
AU2003291967A1 (en) 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1581904A2 (en) 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2513743C (en) 2003-01-28 2013-06-25 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1609802A4 (en) 2003-02-26 2006-06-21 Japan Science & Tech Agency Transcriptional factor inducing apoptosis in cancer cell
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2004084943A1 (en) 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US7632920B2 (en) 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
JP4879020B2 (en) 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド Methods for delivering molecules to cells and carrier complexes
CN102174102A (en) 2003-05-15 2011-09-07 塔夫茨大学信托人 Stable analogs of peptide and polypeptide therapeutics
JP2008516994A (en) 2004-10-20 2008-05-22 セラテクノロジーズ、インコーポレイテッドTheratechnologies Inc. Growth hormone secretagogue and use thereof
WO2004105789A1 (en) 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
AU2003902743A0 (en) 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides
MXPA05013340A (en) 2003-06-09 2006-03-09 Nastech Pharm Co Compositions and methods for enhanced mucosal delivery of growth hormone.
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US20090198050A1 (en) 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
EP1633774B1 (en) 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005000876A2 (en) 2003-06-27 2005-01-06 Proteologics, Inc. Ring finger family proteins and uses related thereto
WO2005007675A2 (en) 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE ϵ-AMINO ACIDS
US20070185031A1 (en) 2003-07-14 2007-08-09 Northwestern University Reducing polyglutamine-based aggregation
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
EP1668116A4 (en) 2003-08-20 2007-08-15 Northern Sydney And Central Co Methods for enhancing embryo viability
US7968080B2 (en) 2003-08-20 2011-06-28 The Regents Of The University Of California Somatostatin analogs with inhibitory activity to growth hormone release
WO2005027913A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
CA2541090C (en) 2003-10-03 2013-04-16 Veijlen N.V. Use of indole acetic acid or derivatives thereof to increase igf-1 serum levels
CA2540452A1 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
GB0323728D0 (en) 2003-10-10 2003-11-12 Royal College Of Surgeons Ie Peptidomimetics and uses thereof
EP1673386A2 (en) 2003-10-16 2006-06-28 AplaGen GmbH Stabilized alpha-helical peptides
WO2005044840A2 (en) 2003-10-17 2005-05-19 The Cbr Institute For Biomedical Research, Inc. Modulation of anergy and methods for isolating anergy-modulating compounds
US7893025B2 (en) 2003-10-20 2011-02-22 Theratechnolgies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US7273927B2 (en) 2003-11-03 2007-09-25 University Of Massachusetts Mdm2 splice variants
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
US20070161551A1 (en) 2004-02-10 2007-07-12 De Luca Giampiero Methods and compositions for the treatment of lipodystrophy
WO2005074521A2 (en) 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
US20050203009A1 (en) 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
CA2603295A1 (en) 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
US7034050B2 (en) 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
CN1953965B (en) 2004-05-18 2012-07-04 霍夫曼-拉罗奇有限公司 Novel cis-imidazolines
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
WO2005118634A2 (en) 2004-06-04 2005-12-15 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity against beta-amyloid production
EP1602663A1 (en) 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
CN100335467C (en) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 Synthesis of 5-iodo-1,4-twice substituted-1,2,3-trioxazole compound
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2006020930A2 (en) 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US20120010157A1 (en) 2004-08-12 2012-01-12 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20080261873A1 (en) 2004-08-18 2008-10-23 Elixir Pharmaceuticals, Inc. Growth-Hormone Secretagogues
US7074775B2 (en) 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7402652B2 (en) 2004-09-14 2008-07-22 Miller Landon C G Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders
US20090275648A1 (en) 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2006137974A2 (en) 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US7425640B2 (en) 2004-10-29 2008-09-16 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
GB0428187D0 (en) 2004-12-23 2005-01-26 Univ Liverpool Cancer treatment
US7157421B2 (en) 2004-12-27 2007-01-02 Miller Landon C G Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
ES2428869T3 (en) 2005-01-24 2013-11-12 Pepscan Systems B.V. Binding compounds, immunogenic and peptidomimetic compounds
FR2881430B1 (en) 2005-02-01 2010-10-22 Servier Lab Novel peptides interacting with anti-apoptotic members of the bcl-2 protein family and uses thereof
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
EP1909854A4 (en) 2005-07-21 2012-02-22 Barry John Allen Method for treating cancer
WO2007014258A2 (en) 2005-07-22 2007-02-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Growth hormone secretagogues
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2007038678A2 (en) 2005-09-28 2007-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogs of ghrelin
US20070161544A1 (en) 2006-01-06 2007-07-12 Peter Wipf Selective targeting agents for mitcochondria
WO2007095347A2 (en) 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions related to ghs-r antagonists
US7745573B2 (en) * 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7538190B2 (en) * 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23592A1 (en) 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Method for preventing and eliminating fibrosis and other forms of pathological deposition in tissues applying secretagogue peptide GHRP-6
AU2007227641B2 (en) 2006-03-13 2012-11-29 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
EP2007716A1 (en) 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
EP2021015A2 (en) 2006-04-28 2009-02-11 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007269836A1 (en) 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
MX2009000132A (en) 2006-06-30 2009-01-26 Schering Corp Method of using substituted piperidines that increase p53 activity.
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008008357A1 (en) 2006-07-11 2008-01-17 Harkness Pharmaceuticals, Inc. Methods of treating obesity using satiety factors
US20100322945A1 (en) 2006-07-26 2010-12-23 Peter Timmerman Immunogenic compounds and protein mimics
US8614192B2 (en) 2006-07-28 2013-12-24 Leiden University Medical Center Method for treating ocular cancer
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
DE602007010664D1 (en) 2006-09-04 2010-12-30 Univ Dundee P53 activating benzoyl hydrogen and benzoylthine oxygen compounds
US20080213175A1 (en) 2006-09-15 2008-09-04 Kolb Hartmuth C Click chemistry-derived cyclic peptidomimetics as integrin markers
US7897394B2 (en) 2006-09-21 2011-03-01 Intrexon Corporation Endoplasmic reticulum localization signals
CA2662838A1 (en) 2006-09-21 2008-03-27 F. Hoffmann-La Roche Ag Oxindole derivatives
RU2459831C2 (en) 2006-09-27 2012-08-27 Ипсен Фарма С.А.С. Analogues of ghrelin substituted at n-end
WO2008040000A2 (en) 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
AU2007307254A1 (en) 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
KR100860060B1 (en) 2006-10-12 2008-09-24 한국과학기술연구원 METHOD FOR QUANTITATIVE ANALYSIS OF INTERACTIONS BETWEEN HIF-1ALPHA C-TERMINAL PEPTIDES AND CBP OR p300 PROTEINS AND METHOD OF SCREENING INHIBITORS AGAINST FORMATION OF PROTEIN COMPLEX USING THE SAME
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
WO2008048942A2 (en) 2006-10-16 2008-04-24 The Salk Institute For Biological Studies Receptor(sstr2)-selective somatostatin antagonists
WO2008061192A2 (en) * 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized maml peptides and uses thereof
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN105061577A (en) 2006-12-14 2015-11-18 爱勒让治疗公司 Bis-sulfhydryl macrocyclization systems
CA2672826A1 (en) 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof
EP2114986B1 (en) 2007-01-29 2013-05-22 Polyphor Ltd. Template-fixed peptidomimetics
ES2558928T3 (en) * 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
CN101244053B (en) 2007-02-16 2010-12-08 石药集团中奇制药技术(石家庄)有限公司 Novel dispersed system with docetaxel as main component
CN104086641A (en) 2007-02-23 2014-10-08 爱勒让治疗公司 Triazole macrocycle systems
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
US8618324B2 (en) 2007-03-13 2013-12-31 Board Of Regents, The University Of Texas System Composition and method for making oligo-benzamide compounds
JP5631201B2 (en) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ Stitched polypeptide
TWI429436B (en) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc Methods of treating or preventing emesis using growth hormone secretagogues
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008137633A2 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
AU2008260483A1 (en) 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
RU2007133287A (en) 2007-09-05 2009-03-10 Ионов Иль Давидович (RU) Antipopsoriatic agent and method of its use (options)
WO2009033668A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187905A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
RU2010114051A (en) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Application of grf-1 (1-29) and corticoliberin as a therapeutic
WO2009039146A1 (en) 2007-09-17 2009-03-26 Olas Pharmaceuticals, Inc. Modulation of growth hormone, dhea, and cortisol with positive modulators of ampa type glutamate receptors
CA2699707C (en) 2007-09-21 2016-05-17 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
WO2009071460A2 (en) 2007-12-03 2009-06-11 Italfarmaco Spa New non-selective somatostatin analogues
CA2710964A1 (en) 2007-12-31 2009-09-11 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
MX2010008110A (en) 2008-01-25 2011-03-04 Trustees Boston College Catalysts for metathesis reactons including enantioselective olefin metathesis, and related methods.
CN106841616B (en) 2008-01-25 2019-06-04 茂体外尔公司 P53 biomarker
US20090275519A1 (en) 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
US20090326192A1 (en) * 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
EP2283033A1 (en) 2008-05-06 2011-02-16 New York Blood Center Antiviral cell penetrating peptides
EP2285970A4 (en) 2008-06-03 2011-10-12 Aileron Therapeutics Inc Compositions and methods for enhancing cellular transport of biomolecules
WO2009149339A2 (en) 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
CN107446053A (en) 2008-06-12 2017-12-08 益普生生物创新有限公司 The suppression of cancer
KR101642363B1 (en) 2008-06-12 2016-07-25 입센 바이오이노베이션 리미티드 Suppression of neuroendocrine diseases
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
US20110158973A1 (en) 2008-06-12 2011-06-30 Syntaxin Limited Suppression of cancers
JP5627581B2 (en) 2008-06-25 2014-11-19 ブラーシュ・バイオテック・エルエルシー Compositions and methods for enhancing somatostatin immunogenicity
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
AU2009294871A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
ES2666458T3 (en) * 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. peptidomimetic macrocycles
EP2331567A1 (en) 2008-09-22 2011-06-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737921C (en) 2008-09-22 2019-01-15 Aileron Therapeutics, Inc. Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
CN102884074A (en) 2008-09-22 2013-01-16 爱勒让治疗公司 Peptidomimetic macrocycles
WO2010034026A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2999537A1 (en) 2008-10-10 2010-04-15 Dana Farber Cancer Institute Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
JP2010120881A (en) 2008-11-19 2010-06-03 Keio Gijuku PEPTIDE FOR INHIBITING INTERACTION BETWEEN HUMAN CANCER PROTEIN MDM2 AND HUMAN CANCER-INHIBITING PROTEIN p53, AND USE THEREOF
KR101298168B1 (en) 2008-11-21 2013-08-20 충남대학교산학협력단 Chemical inhibitor of snail―p53 binding and pharmaceutical composition for treating cancer disease comprising the same
BRPI0920899A2 (en) 2008-11-24 2016-04-26 Aileron Therapeutics Inc Peptidomimetic macrocycles with improved properties
WO2010065572A1 (en) 2008-12-04 2010-06-10 The Salk Institute For Biological Studies Sstr1-selective analogs
EP3124494B1 (en) 2008-12-09 2019-06-19 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US20100152114A1 (en) 2008-12-12 2010-06-17 Univ Of Miami And Usa By Dept Of Veterans Affairs Antioxidant activity of GH-RH Antagonists
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010083501A2 (en) 2009-01-16 2010-07-22 University Of South Florida Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20100239589A1 (en) 2009-02-23 2010-09-23 Salk Institute For Biological Studies Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof
FR2942798B1 (en) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides useful for the treatment of chronic lymphocytic leukemia
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
US20100267636A1 (en) 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
US8666718B2 (en) 2009-04-22 2014-03-04 The Walter And Eliza Hall Institute Of Medical Research Structure of the C-terminal region of the insulin receptor α-chain and of the insulin-like growth factor receptor α-chain
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
WO2010132580A2 (en) 2009-05-12 2010-11-18 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
JP2010286127A (en) 2009-06-09 2010-12-24 Daikin Ind Ltd Adsorption heat exchanger
WO2011005219A1 (en) 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
US9163330B2 (en) * 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2470502A1 (en) 2009-08-26 2012-07-04 Novartis AG Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
EA201270497A1 (en) 2009-09-30 2012-10-30 Транзайм Фарма, Инк. Salts, solvates and pharmaceutical compositions of macro-cyclic agonists of grelin receptor and methods of their application
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
JP2013507927A (en) 2009-10-14 2013-03-07 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Improved peptidomimetic macrocycles
US20110105389A1 (en) 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
RU2576512C2 (en) 2009-11-04 2016-03-10 Хэлс Ресеч Инк. Method and compositions for ageing suppression
UA107814C2 (en) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Spiro-oxindoles antagonists mdm 2
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
KR101220516B1 (en) 2010-01-21 2013-01-10 연세대학교 산학협력단 Human Adult Stem Cells Secreting Anti-MDM2 and Uses thereof
EP2534140B1 (en) 2010-02-08 2018-04-11 Trustees of Boston College Efficient methods for z- or cis-selective cross-metathesis
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
WO2011127058A2 (en) 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
KR20130111923A (en) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
US9315546B2 (en) 2010-06-16 2016-04-19 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
US20110313167A1 (en) 2010-06-22 2011-12-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Substituted Heterocycles as Therapeutic agents for treating cancer
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CA2796879A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
RU2582678C2 (en) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles
EP2614051A4 (en) 2010-09-08 2014-01-29 Univ Pittsburgh P53-mdm2 antagonists
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
WO2012037519A2 (en) 2010-09-16 2012-03-22 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
CN102399284B (en) 2010-09-17 2013-05-29 中国农业大学 Fox growth hormone releasing hormone cDNA and its application
CN102399283B (en) 2010-09-17 2013-05-29 中国农业大学 Mink growth hormone releasing hormone cDNA and application thereof
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012047587A2 (en) 2010-09-27 2012-04-12 Serrata, Llc Mdm2 inhibitors for treatment of ocular conditions
EP2621275B1 (en) 2010-09-30 2018-03-28 St. Jude Children's Research Hospital Aryl-substituted imidazoles
WO2012051405A1 (en) 2010-10-13 2012-04-19 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
FR2967072B1 (en) 2010-11-05 2013-03-29 Univ Dundee Process for improving influenza production of vaccine and seeds
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
US8680132B2 (en) 2010-11-12 2014-03-25 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
ES2528376T3 (en) 2010-11-19 2015-02-09 Novartis Ag Crystalline form of an MDM2 / 4 and p53 interaction inhibitor
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
EP2651964B1 (en) 2010-12-15 2018-02-28 The Research Foundation of State University of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
WO2012083181A1 (en) 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
BR112013014522A2 (en) 2010-12-16 2017-09-26 Roche Glycart Ag afucosylated anti-cd20 antibody and its use, composition and method for treating a cancer patient
CN103261188A (en) 2010-12-17 2013-08-21 先正达参股股份有限公司 Insecticidal compounds
EP2474624B1 (en) 2011-01-05 2016-08-17 Daniela Kandioler Response prediction in cancer treatment (p53 adapted cancer therapy)
EP2474625B1 (en) 2011-01-05 2016-11-02 Daniela Kandioler Method for determining the p53 status of a tumour
US20130302909A1 (en) 2011-01-14 2013-11-14 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
JP5950587B2 (en) 2011-02-28 2016-07-13 キヤノン株式会社 Method for producing porous glass and method for producing optical member
WO2012122059A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
DK2684888T3 (en) 2011-03-09 2019-08-19 Jitsubo Co Ltd New crosslinked peptides containing non-peptide crosslinked structure, process for synthesizing crosslinked peptides and new organic compound used in the process
US8629133B2 (en) 2011-03-10 2014-01-14 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
AU2012249301A1 (en) 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
US20120328692A1 (en) 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
AU2012301605A1 (en) 2011-08-31 2014-04-17 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
EP2753635A4 (en) 2011-09-09 2015-08-12 Agency Science Tech & Res P53 activating peptides
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CA2872147A1 (en) 2012-05-02 2013-11-07 Kansas State University Research Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2761253A1 (en) 2011-12-07 2013-06-07 Vib Vzw Combinations of therapeutic agents for treating melanoma
US9464125B2 (en) 2012-02-03 2016-10-11 The Trustees Of Princeton University Engineered potent cytotoxic stapled BH3 peptides
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013130791A1 (en) 2012-02-29 2013-09-06 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
US9880171B2 (en) 2012-03-02 2018-01-30 Ludwig Institute For Cancer Research Ltd. iASPP phosphorylation and metastatic potential
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
CN104520714A (en) 2012-07-31 2015-04-15 诺华股份有限公司 Markers associated with sensitivity to inhibitors of human double minute 2 (MDM2)
EP2901154B1 (en) 2012-09-25 2018-11-21 The Walter and Eliza Hall Institute of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
CA2925035A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
KR20150131244A (en) 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stapled and stitched polypeptides and uses thereof
CN105102635A (en) 2013-03-15 2015-11-25 生命技术公司 Classification and actionability indices for lung cancer
US9198910B2 (en) 2013-04-04 2015-12-01 The Translational Genomics Research Institute Methods for the treatment of cancer
WO2014172479A1 (en) 2013-04-16 2014-10-23 Memorial Sloan-Kettering Cancer Center Companion diagnostic for cdk4 inhibitors
US20160122405A1 (en) 2013-06-06 2016-05-05 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
CA2915354A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
JP6461126B2 (en) 2013-07-03 2019-01-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト MRNA-based gene expression for personalizing cancer therapy in patients using MDM2 antagonists
US9268662B2 (en) 2013-08-01 2016-02-23 Oracle International Corporation Method and system for a high availability framework
CA2919837A1 (en) 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
EP3052520A4 (en) 2013-10-01 2017-12-06 President and Fellows of Harvard College Stabilized polypeptides and uses thereof
US20160115556A1 (en) 2013-10-19 2016-04-28 Trovagene, Inc. Detecting mutations in disease over time
SG10201902429PA (en) 2013-11-11 2019-04-29 Amgen Inc Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CA2926307A1 (en) 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
AU2014372166B2 (en) 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
RU2684106C2 (en) 2013-12-23 2019-04-04 Новартис Аг Pharmaceutical combinations
WO2015108175A1 (en) 2014-01-14 2015-07-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
WO2015157508A1 (en) 2014-04-09 2015-10-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
US20170184604A1 (en) 2014-05-22 2017-06-29 The General Hospital Corporation Dd1alpha receptor and uses thereof in immune disorders
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
US20170296659A1 (en) 2014-09-13 2017-10-19 Novartis Ag Combination therapies
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20170283885A1 (en) 2014-10-09 2017-10-05 Daiichi Sankyo Company, Limited Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors
WO2016055497A1 (en) 2014-10-10 2016-04-14 F. Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR20170095893A (en) 2014-12-24 2017-08-23 제넨테크, 인크. Therapeutic, diagnostic, and prognostic methods for cancer of the bladder
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2989311A1 (en) 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
WO2017023933A2 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2996685A1 (en) 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US20170349638A1 (en) 2016-03-21 2017-12-07 Aileron Therapeutics, Inc. Companion diagnostic tool for peptidomimetic macrocycles
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
WO2017218949A2 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Also Published As

Publication number Publication date
CN101730708A (en) 2010-06-09
JP2010522769A (en) 2010-07-08
JP6363122B2 (en) 2018-07-25
WO2008121767A2 (en) 2008-10-09
JP2016094476A (en) 2016-05-26
KR20140117695A (en) 2014-10-07
US20100184645A1 (en) 2010-07-22
US20170066799A1 (en) 2017-03-09
JP2014193932A (en) 2014-10-09
EP3159352A1 (en) 2017-04-26
ES2610531T3 (en) 2017-04-28
HK1140215A1 (en) 2014-04-04
IL221062A (en) 2018-06-28
KR101525754B1 (en) 2015-06-09
AU2008232709A1 (en) 2008-10-09
IL201227A (en) 2017-11-30
EP2142562B1 (en) 2013-07-03
US8592377B2 (en) 2013-11-26
KR101623985B1 (en) 2016-05-25
CN101730708B (en) 2013-09-18
AU2008232709B2 (en) 2014-05-29
EP2142562A2 (en) 2010-01-13
WO2008121767A3 (en) 2009-01-08
BRPI0809366A2 (en) 2014-09-16
AU2008232709C1 (en) 2015-01-15
EP2508531A1 (en) 2012-10-10
CA2682174A1 (en) 2008-10-09
US10301351B2 (en) 2019-05-28
KR20090126308A (en) 2009-12-08
EP2508531B1 (en) 2016-10-19
KR20160061439A (en) 2016-05-31
JP5631201B2 (en) 2014-11-26
BRPI0809366A8 (en) 2019-01-29
US9556227B2 (en) 2017-01-31
US20140011979A1 (en) 2014-01-09
JP2018044018A (en) 2018-03-22
ES2430067T3 (en) 2013-11-18
IL201227D0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
EG24811A (en) Scorch-retarding polymer composition.
MXPA06014684A (en) Novel antigen-binding polypeptides and their uses.
IL233634D0 (en) Methods, compositions, and kits for the treatment of medical conditions
LTC1971366I2 (en) Human anti-IL-23 antibodies, compositions, methods, and uses
IL197185A (en) Substituted acylanilide, composition comprising it and uses thereof
EP1853295A4 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL184550D0 (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
IL185906D0 (en) Composition
IL205581A (en) Quinoline derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2008121563A3 (en) Modified fgf-21 polypeptides and their uses
EP1940441A4 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2006017538A3 (en) Hk1-binding proteins
WO2009067636A3 (en) Modified insulin polypeptides and their uses
EP1879659A4 (en) Low-irritation compositions and methods of making the same
EP1930012A4 (en) Cellooligosaccharide-containing composition
MX2012007507A (en) Heteroaryl compounds and uses thereof.
MX2011011093A (en) Heteroaryl compounds and uses thereof.
MX2008012929A (en) Kinase antagonists.
DE602006009684D1 (en) Intermediate implant for the lumbosakralgelenk
IL200684D0 (en) Heterocyclic cyclopamine analog compounds, compositions comprising the same and uses thereof
IL189103D0 (en) Processes for the manufacture of sterilized pancreation powder
IL200746D0 (en) Cyclopamine analog compounds, compositions comprising the same and uses thereof
AP200704274A0 (en) Immunogenic composition
SG195536A1 (en) Bispecific anti-vegf/anti-ang-2 antibodies
EP1985582A4 (en) Chlorine dioxide generating composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed